Patient-Reported Outcomes in Chronic Migraine Patients Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study

被引：0
|
作者：
Tepper, S. [1 ]
Lipton, R. [2 ]
Reuter, U. [3 ]
Silberstein, S. [4 ]
Stewart, W. [5 ]
Leonardi, D. [6 ]
Desai, P. [7 ]
Cheng, S. [8 ]
Mikol, D. [8 ]
Lenz, R. [8 ]
机构：
[1] Geisel Sch Med Dartmouth, Hanover, NH USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Charite, Dept Neurol, Berlin, Germany
[4] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[5] Sutter Hlth, Walnut Creek, CA USA
[6] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[7] Global Hlth Econ, Thousand Oaks, CA USA
[8] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
来源：
CEPHALALGIA | 2016年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTC-0423
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [1] Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study
    Tepper, Stewart
    Lipton, Richard
    Reuter, Uwe
    Silberstein, Stephen
    Stewart, Walter
    Leonardi, Dean
    Desai, Pooja
    Cheng, Sunfa
    Mikol, Dan
    Lenz, Robert
    NEUROLOGY, 2017, 88
  • [2] Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study
    Lipton, R. B.
    Tepper, S. J.
    Reuter, U.
    Silberstein, S. D.
    Stewart, W. F.
    Leonardi, D. K.
    Desai, P.
    Cheng, S.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 198 - 198
  • [3] Patient-reported outcomes in patients with chronic migraine receiving placebo or erenumab (AMG 334) in a phase 2, randomised, double-blind study
    Lipton, Richard B.
    Tepper, Stewart J.
    Reuter, Uwe
    Silberstein, Stephen
    Stewart, Walter
    Leonardi, Dean
    Desai, Pooja
    Cheng, Sunfa
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [4] Erenumab in chronic migraine Patient-reported outcomes in a randomized double-blind study
    Lipton, Richard B.
    Tepper, Stewart J.
    Reuter, Uwe
    Silberstein, Stephen
    Stewart, Walter F.
    Nilsen, Jon
    Leonardi, Dean K.
    Desai, Pooja
    Cheng, Sunfa
    Mikol, Daniel D.
    Lenz, Robert
    NEUROLOGY, 2019, 92 (19) : E2250 - E2260
  • [5] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
    Tepper, S. J.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. L.
    Silberstein, S. D.
    Winner, P.
    Leonardi, D. K.
    Mikol, D. D.
    HEADACHE, 2017, 57 : 130 - 130
  • [6] Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
    Tepper, Stewart
    Widnell, Katherine
    Dolezil, David
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Silberstein, Stephen
    Winner, Paul
    Leonardi, Dean
    Mikol, Dan
    NEUROLOGY, 2017, 88
  • [7] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
    Tepper, S.
    Widnell, K.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. Lewis
    Silberstein, S.
    Winner, P.
    Leonardi, D.
    Mikol, D.
    CEPHALALGIA, 2016, 36 : 44 - 45
  • [8] Patient-Reported Outcomes from the ARISE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
    Ashina, M.
    Brandes, J. L.
    Katsarava, Z.
    Lipton, R. B.
    Pascual, J.
    Palmer, K.
    Desai, P.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 192 - 192
  • [9] Patient-Reported Outcomes from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
    Buse, D. C.
    Lipton, R. B.
    Hallstrom, Y.
    Reuter, U.
    Tepper, S. J.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 198 - 199
  • [10] Efficacy of erenumab (AMG 334) in patients with chronic migraine in North America and Europe: Subgroup analysis of a phase 2, randomised, double-blind, placebo-controlled study
    Reuter, U.
    Brandes, J.
    Dolezil, D.
    Tepper, S.
    Cheng, S.
    Leonardi, D.
    Lenz, R.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 548 - 548
12345